Lucía Rodríguez‐Vázquez
A5008224086- Pregnancy and preeclampsia studies
- Glioma Diagnosis and Treatment
- HIV/AIDS Research and Interventions
- Neurological Complications and Syndromes
- Intracerebral and Subarachnoid Hemorrhage Research
- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- Pregnancy and Medication Impact
- Neurogenesis and neuroplasticity mechanisms
- Pharmacological Effects and Toxicity Studies
- Amino Acid Enzymes and Metabolism
- Cancer, Hypoxia, and Metabolism
- COVID-19 Impact on Reproduction
- COVID-19 Clinical Research Studies
- COVID-19 and healthcare impacts
- Advanced biosensing and bioanalysis techniques
- MicroRNA in disease regulation
- Neuroinflammation and Neurodegeneration Mechanisms
- Folate and B Vitamins Research
- Neonatal and fetal brain pathology
- Neonatal Health and Biochemistry
- Prenatal Substance Exposure Effects
- RNA Research and Splicing
- Heme Oxygenase-1 and Carbon Monoxide
- DNA Repair Mechanisms
Vall d'Hebron Institut de Recerca
2023
Vall d'Hebron Hospital Universitari
2023
Universitat Autònoma de Barcelona
2016-2020
BackgroundFactors affecting outcomes of SARS-CoV-2 infection in people living with HIV are unclear. We assessed the factors associated diagnosis and severe among HIV.MethodsWe did a retrospective cohort study using data from PISCIS Catalonia (Spain) between March 1 Dec 15, 2020. linked integrated health-care, clinical, surveillance registries through Public Data Analysis for Health Research Innovation Program (PADRIS) to obtain on diagnosis, chronic comorbidities, as well clinical mortality...
Reports on the impact of some antiretrovirals against SARS-CoV-2 infection and disease severity are conflicting.We evaluated effect tenofovir as either alafenamide/emtricitabine (TAF/FTC) or disoproxil fumarate/emtricitabine (TDF/FTC) associated clinical outcomes among people living with HIV (PLWH).We conducted a propensity score-matched analysis in prospective PISCIS cohort PLWH (n = 14 978) Catalonia, Spain. We used adjusted Cox regression models to assess association between...
To assess the clinical and immunovirological outcomes among naive patients with advanced HIV presentation starting an antiretroviral regimen in real-life settings.This was a multicentre, prospective cohort study. We included all treatment-naive adults disease (CD4+ T cell count < 200 cells/mm3or presence of AIDS-defining illness) who started therapy between 2010 2020. The main were mortality, virological effectiveness (percentage viral load ≤50 copies/mL) immune restoration CD4+ above 350...
We aimed to determine if starting antiretroviral therapy (ART) in the first 30 days after acquiring HIV infection has an impact on immunovirological response.Observational, ambispective study including 147 patients with confirmed acute (January/1995-August/2022). ART was defined as very early (≤30 estimated date of infection), (31-180 days), and late (>180 days). compared time viral suppression (viral load [VL] <50 copies/ml) immune recovery (IR) (CD4+/CD8+ ratio ≥1) according timing type...
The current study was conducted to assess whether a single administration of 5-bromo-2'-deoxyuridine (BrdU) interferes with cell proliferation and leads the activation apoptotic cellular events in prenatal cerebellum. BrdU effects across wide range doses (25-300 μg/g b.w.) were analyzed using immunohistochemical ultrastructural procedures. pregnant rats injected at embryonic day 13, their fetuses sacrificed from 5 35 hr after exposure. quantification several parameters such as density...
Cerebellar neurons are generated from the rhombic lip and neuroepithelium. In this study, we analyze histogenesis of cerebellar neuroepithelium in terms cellular kinetics. The experimental animals offspring pregnant dams injected with 5-bromo-2ʹ-deoxyuridine (BrdU) on embryonic day 13. We infer fraction S-phase cells by examining a range survival times after single BrdU-exposure cumulative BrdU-labeling sequence, which allow for derivation cell-cycle parameters phase durations. current...
The cytostatic agent hydroxyurea (HU) has proven to be beneficial for a variety of conditions in the disciplines oncology, hematology, infectious disease and dermatology. It disrupts S-phase cell cycle by inhibiting ribonucleotide reductase enzyme, thus blocking transformation ribonucleotides into deoxyribonucleotides, rate limiting step DNA synthesis. HU is listed as an essential medicine World Health Organization. Several studies have indicated that well tolerated safe pregnant women very...